Showing all 3 results
Everolimus Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Antioxidant-Stabilized Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical survival of the highly oxidative, potent API.
Active Ingredient Strength Primary Clinical Function Everolimus USP/Ph.Eur. 0.25 mg / 0.5 mg / 0.75 mg Global Transplant Standard: Ultra-micro doses utilized for strict, lifelong immunosuppression following renal or hepatic allografts. Requires extreme content uniformity to maintain the narrow therapeutic blood trough levels (3 to 8 ng/mL). Everolimus USP/Ph.Eur. 5 mg / 10 mg Global Oncology Standard: Massive-dose antineoplastic payload utilized for the aggressive suppression of Renal Cell Carcinoma, Neuroendocrine Tumors (NETs), and HR+/HER2- Breast Cancer. Excipients Butylated Hydroxytoluene (BHT) / Hypromellose / Lactose Anhydrous / Crospovidone / Magnesium Stearate Antioxidant / Binder / Diluent / Superdisintegrant / Lubricant (Engineered specifically utilizing BHT (Butylated Hydroxytoluene) to prevent the rapid oxidative degradation of the Everolimus molecule, guaranteeing maximum clinical shelf-life and potency across harsh climates) *Pack Sizes: 10×10 Alu-Alu Blisters (Transplant) or 3×10 Alu-Alu Blisters (Oncology – 30 Day Supply).
Pazopanib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered, High-Density Film-Coated Tablet, packed exclusively in highly secure, child-resistant heavy-gauge HDPE bottles or specialized Alu-Alu blister strips to ensure the absolute chemical stability of the cytotoxic molecule and prevent accidental exposure.
Active Ingredient Strength Primary Clinical Function Pazopanib HCl INN/Ph.Eur. 200 mg (Base Equivalent) Dose-Modification Standard: Essential unit for precise dose reduction in patients experiencing severe hepatic toxicity or adverse drug reactions. Pazopanib HCl INN/Ph.Eur. 400 mg (Base Equivalent) Global Clinical Standard: Primary therapeutic unit designed to achieve the massive 800 mg daily protocol with minimal pill burden. Excipients Microcrystalline Cellulose / Sodium Starch Glycolate / Povidone K30 / Magnesium Stearate / Hypromellose / Titanium Dioxide Diluent / Superdisintegrant / Binder / Lubricant / Premium Cytotoxic-Barrier Film-Coating (Engineered specifically to seal the lethal HPAPI inside the tablet, completely protecting healthcare workers and caregivers from highly toxic dust exposure) *Pack Sizes: Bottles of 30 or 60 Tablets (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Sorafenib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed in highly secure, child-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute stability of the tosylate salt formulation.
Active Ingredient Strength Primary Clinical Function Sorafenib Tosylate INN/Ph.Eur. 200 mg (Equivalent to Sorafenib free base) Global Standard: Base titration unit for the standard 800 mg daily oncology regimen. Excipients Croscarmellose Sodium / Microcrystalline Cellulose / Hypromellose / Magnesium Stearate Superdisintegrant / Diluent / Film-Coating (Engineered for strict gastric dissolution and reliable systemic bioavailability)
